VRTX
福泰 VERTEX PHARMACEUTICALS INC / MA
-0.35 (-0.07%)512.91USD239K成交股數130B市值29.9本益比(近四季)10.3股價營收比+12.4%營收年增(近四季)2026-11-02下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 3.3B+20% | 3.0B+3% | 3.1B+11% | 3.0B+12% | 2.8B+3% | 2.9B+17% | 2.8B+11% | 2.6B+11% | 2.7B | 2.5B | 2.5B | 2.4B |
| 營業成本 | 489M | 393M | 415M | 408M | 363M | 423M | 393M | 372M | 343M | 319M | 309M | 267M |
| 毛利 | 2.8B+18% | 2.6B+4% | 2.7B+12% | 2.6B+12% | 2.4B+3% | 2.5B+15% | 2.4B+9% | 2.3B+8% | 2.3B | 2.2B | 2.2B | 2.1B |
| 毛利率 | 85.3% | 86.8% | 86.5% | 86.3% | 86.9% | 85.5% | 85.8% | 85.9% | 87.3% | 87.2% | 87.6% | 88.8% |
| 研發費用 | 994M | 962M | 978M | 978M | 980M | 999M | 876M | 967M | 789M | 810M | 786M | 743M |
| 銷售管理費用 | 582M | 494M | 445M | 425M | 396M | 378M | 372M | 372M | 343M | 264M | 263M | 241M |
| 營業利益 | 1.2B+98% | 1.1B+11% | 1.2B+6% | 1.2B-133% | 630M-45% | 1.0B-1% | 1.1B+9% | −3.5B-551% | 1.1B | 1.0B | 1.0B | 779M |
| 營業利益率 | 37.4% | 38.1% | 38.6% | 38.8% | 22.7% | 35.2% | 40.3% | -132.9% | 42.4% | 41.8% | 41.2% | 32.8% |
| 稅後淨利 | 1.1B+70% | 1.0B+13% | 1.1B+4% | 1.0B-129% | 646M-41% | 913M-12% | 1.0B+14% | −3.6B-614% | 1.1B | 1.0B | 916M | 700M |
| 淨利率 | 33.0% | 34.5% | 35.2% | 34.8% | 23.3% | 31.4% | 37.7% | -135.8% | 40.9% | 41.7% | 36.7% | 29.5% |
| 稀釋 EPS | 4.31+73% | 4.02+11% | 4.20+5% | 3.99-129% | 2.49-41% | 3.62-9% | 4.01+14% | -13.92-617% | 4.21 | 3.97 | 3.52 | 2.69 |
| 稀釋股數 | 255M | 256M | 258M | 259M | 260M | 258M | 261M | 258M | 261M | 261M | 260M | 260M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 6.1B | 5.5B | 4.9B | 5.0B | 4.7B | 4.6B | 5.2B | 4.6B | 9.2B | 11.1B | 10.2B | 9.3B |
| 應收帳款 | 2.1B | 2.0B | 1.9B | 1.9B | 1.8B | 1.6B | 1.8B | 1.7B | 1.8B | 1.5B | 1.6B | 1.5B |
| 存貨 | 1.8B | 1.8B | 1.6B | 1.5B | 1.4B | 1.2B | 1.1B | 915M | 813M | 689M | 604M | 535M |
| 總資產 | 27.4B | 26.5B | 24.9B | 24.0B | 22.9B | 22.5B | 22.2B | 20.1B | 23.9B | 21.7B | 20.3B | 19.0B |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 7.2B | 7.1B | 7.5B | 6.9B | 6.4B | 6.1B | 6.6B | 5.4B | 5.4B | 5.2B | 4.9B | 4.5B |
| 股東權益 | 20.2B | 19.4B | 17.3B | 17.2B | 16.5B | 16.4B | 15.6B | 14.8B | 18.5B | 16.5B | 15.5B | 14.4B |
| 負債比 | 26.2% | 26.9% | 30.3% | 28.5% | 27.9% | 27.2% | 29.7% | 26.6% | 22.5% | 24.0% | 24.0% | 23.9% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 1.4B | – | – | 819M-37% | – | – | – | 1.3B | – | – | 900M |
| 資本支出 | – | 133M | – | – | 40.7M | – | – | – | 68.4M | – | – | 42.1M |
| 自由現金流 | – | 1.3B | – | – | 778M-37% | – | – | – | 1.2B | – | – | 858M |
| 折舊攤銷 | 56.5M | 55.9M | 54.0M | 51.7M | 48.4M | 46.5M | 53.2M | 54.0M | 53.5M | – | – | 38.8M |
| 買回庫藏股 | – | 337M | – | – | 426M | – | – | – | 131M | – | – | 133M |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 43.3% | – | – | 28.1% | – | – | – | 46.0% | – | – | 36.1% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 12.0B
| Pharmaceuticals | 12.0B | 100.0% | +8.9% |
|---|
地區2025 年度 · 12.0B
| 美國 | 7.5B | 62.9% | +12.9% |
|---|---|---|---|
| 歐洲 | 3.5B | 28.8% | +0.2% |
| Other Countries Outsideofthe United Statesand Europe | 992M | 8.3% | +12.6% |
| Outsidethe United States 小計 | 4.5B | 37.1% | +2.7% |
產品／服務2025 年度 · 12.2B
| TRIKAFTAKAFTRIO | 10.3B | 84.7% | +0.7% |
|---|---|---|---|
| ALYFTREK | 838M | 6.9% | – |
| Manufactured Product Other | 820M | 6.7% | +4.9% |
| CASGEVY | 116M | 1.0% | +1058.0% |
| JOURNAVX | 59.6M | 0.5% | – |
| Collaborativeand Royalty | 30.7M | 0.3% | – |
| 產品 小計 | 12.0B | 98.3% | +8.6% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 12.0B | +8.9% | 4.0B | 32.9% | 15.32 | 3.2B |
| FY2024 | 11.0B | +11.7% | −536M | -4.9% | -2.08 | −790M |
| FY2023 | 9.9B | +10.5% | 3.6B | 36.7% | 13.89 | 3.3B |
| FY2022 | 8.9B | +17.9% | 3.3B | 37.2% | 12.82 | 3.9B |
| FY2021 | 7.6B | +22.1% | 2.3B | 30.9% | 9.01 | 2.4B |
| FY2020 | 6.2B | +49.1% | 2.7B | 43.7% | 10.29 | 3.0B |
| FY2019 | 4.2B | +36.6% | 1.2B | 28.3% | 4.51 | 1.5B |
| FY2018 | 3.0B | – | 2.1B | 68.8% | 8.09 | 1.2B |